Patheon wins a new contract from Boehringer Ingelheim, Ferring buys a UK plant, plus updates from InvaGen, CrossJect and contract …
Sir Christopher Evans is looking to create a new venture that aims to improve on the drug development productivity of …

The US FDA has issued a warning letter to GlaxoSmithKline, noting that its manufacturing plant in Worthing, UK, failed to …

Sanofi’s investigational multiple sclerosis drug Lemtrada has beaten Rebif in a late-stage trial. The Phase III results show that 78% …
France’s Flamel Technologies has won a long-term contract from GlaxoSmithKline focusing on the production of the drugmaker’s Coreg CR heart …
Recently in the UK there has been a move towards risk-based inspection programmes. The scope, frequency and depth of MHRA …

Scammers are exploiting Twitter to entice people into buying fake medicines, according to a new report. The report, published by …

I am always guided by the motto of the Royal Society, ‘Nullius in Verba’. This means, with typical Latin brevity: …
The Deloitte UK Technology Fast 50 was founded in 1998, and remains one of Britain’s foremost technology programs. The program …

Singapore has reinforced its position as a major pharmaceutical hub for the Asia-Pacific region with the news that Merck is …
BMS has made three changes to its senior management with Giovanni Caforio promoted to president of US pharmaceuticals and Charles …
Merck Serono has returned the rights to the Parkinson’s disease drug safinamide back to Newron. The decision comes after the …
The number of regional groups preparing to take over control of the NHS in England is rapidly shrinking, as the …
Amgen has appointed Tony Hooper as the new executive vice president of global commercial operations. Hooper, 56, joins Amgen after …
Abbott’s new spin-off pharma firm could attract a lot of attention from big pharma looking to sure up their portfolios. …

The ABPI has warned that the UK must continue to attract investment for research, or risk being superseded by emerging …

Abbott’s management has decided to split the company into two separate entities in order to give shareholders a ‘distinct investment …

Rumours are gathering pace that GlaxoSmithKline may launch a takeover bid for struggling US firm Human Genome Sciences. British tabloid …

An injectable version of Roche’s breast cancer drug Herceptin compares favourably to the standard intravenous infusion, according to new research. …